DGAP-News: Eckert & Ziegler: 1,000th patient Treated with I-125 implants at Christie Hospital, Manchester - England

Eckert & Ziegler Strahlen- und Medizintechnik AG / Miscellaneous

10.07.2009 

Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Berlin, 10.07.2009 - Belgian Medical Device Company International
Brachytherapy S.A. (IBt Bebig), a portfolio company of Eckert & Ziegler AG
(ISIN DE0005659700), can now also point to a high volume reference hospital
in the United Kingdom for its brachytherapy product against early forms of
prostate cancer.

Christie Hospital located in Manchester, United Kingdom, is one of Europe's
leading cancer centers, treating over 40,000 patients a year and is an
acknowledged leader in international research. The prostate cancer
brachytherapy program is the largest in the U.K and has just treated its
1,000th patient using iodine-125 permanent brachytherapy implants.

Cooperation between Christie Hospital and the IBt Bebig group dates back to
2006. Dr.  James Wylie, Radiation Oncologist, commented: 'Our excellent
working relationship with IBt Bebig has greatly facilitated this cancer
treatment program and we now plan to be collaborating with IBt Bebig on the
development of new products'.

The brachytherapy treatment of early stage prostate cancer - for which IBt
Bebig is today recognized specialist in Europe and leader in its segment -
is being applied increasingly across the continent, where more than 135,000
new cases of prostate cancer are diagnosed every year. Of this number, just
over 12,000 men are treated with permanent brachytherapy implants. For
comparison purposes, this number is four times higher in the USA.

On IBt Bebig:
IBt Bebig develops, produces, and sells radiation-technology products for
the treatment of cancer, in particular prostate cancer, worldwide. The
company with its approx. 150 employees is market leader in Europe for weak
radioactive prostate cancer implants. The company's head office is in
Brussels, the main production site is in Berlin. Eckert & Ziegler holds
almost 40% of the economic shares of the company and 29.9% of the voting
rights in the annual general meeting. Eckert & Ziegler owns an option for
another 21% of the annual general meeting's voting rights.


Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112
E-Mail: karolin.riehle@ezag.de, www.ezag.de


DGAP 10.07.2009 
---------------------------------------------------------------------------
 
Language:     English
Issuer:       Eckert & Ziegler Strahlen- und Medizintechnik AG
              Robert-Rössle-Str.10
              13125 Berlin
              Deutschland
Phone:        49 30 941084138
Fax:          49 30 941084112
E-mail:       karolin.riehle@ezag.de
Internet:     www.ezag.de
ISIN:         DE0005659700, ISIN DE0005659700
WKN:          565970, ISIN DE000A0L1L69
Listed:       Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
              Freiverkehr in Berlin, München, Düsseldorf, Hamburg
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------